Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Lupin makes and sells generic medicines and specialty drugs worldwide.
Lupin Limited is an Indian drugmaker that mostly sells copycat versions of medicines whose patents have expired. These are called generics. When a drug like a blood-pressure pill or an antibiotic loses its patent protection, Lupin can manufacture the same molecule and sell it far cheaper than the original brand. Its customers are pharmacies, hospitals, governments, and other drug companies, mainly in the United States, India, and other markets. The US is its biggest single market, and that is where the money mostly comes from. It also makes "complex generics" — harder-to-copy products like inhalers, injectables, and eye drops — which face less competition and earn better margins.
Think of it as the store-brand version of the medicine cabinet: same active ingredient, much lower price, made at industrial scale. The business splits into a few pieces. Generics bring in the bulk of revenue, spread across the US, India, and other countries. A smaller but growing piece is specialty drugs, where Lupin sells its own branded products, for example treatments for respiratory conditions. Another piece is active pharmaceutical ingredients — the raw chemical powder that goes into pills — which Lupin sells to other manufacturers. Over the last couple of years the company has leaned hard into specialty and complex generics to escape the brutal price wars of simple generics, and that shift has lifted both sales and profits.
Lupin started in 1968 as a small operation making vitamin and drug ingredients, founded by Desh Bandhu Gupta, a former professor. It grew into one of India's largest pharma exporters, with a big bet on the US market that paid off enormously — until it didn't. Around 2017 and 2018, US regulators flagged manufacturing problems at key plants, which froze new approvals and hammered profits. Management spent years fixing quality systems, and the recovery since has been real: revenue is now growing at a healthy double-digit clip and margins have widened. Today the company uses its free cash flow to fund research on complex and specialty products, pay down debt, and return money to shareholders through dividends and buybacks. The main risks are familiar to anyone in generics: price erosion in the US, regulatory inspections, and the constant race to be first with a cheap version of the next big drug going off patent.
Saved answer · last researched 11 Oct 2026